|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11 (Internet). International Agency
for Research on Cancer. Lyon, France: 2013 HTTP://GLOBOCAN.IARC.FRDec 01–2014.
|
|
2
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Popovic R and Licht JD: Emerging
epigenetic targets and therapies in cancer medicine. Cancer Discov.
2:405–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chakravarthi BV, Nepal S and Varambally S:
Genomic and epigenomic alterations in cancer. Am J Pathol.
186:1724–1735. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang H, Salz T, Zajac-Kaye M, Liao D,
Huang S and Qiu Y: Overexpression of histone deacetylases in cancer
cells is controlled by interplay of transcription factors and
epigenetic modulators. FASEB J. 28:4265–4279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan HM and La Thangue NB: p300/CBP
proteins: HATs for transcriptional bridges and scaffolds. J Cell
Sci. 114:2363–2373. 2001.PubMed/NCBI
|
|
7
|
Iyer NG, Ozdag H and Caldas C: p300/CBP
and cancer. Oncogene. 23:4225–4231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muraoka M, Konishi M, Kikuchi-Yanoshita R,
Tanaka K, Shitara N, Chong JM, Iwama T and Miyaki M: p300 gene
alterations in colorectal and gastric carcinomas. Oncogene.
12:1565–1569. 1996.PubMed/NCBI
|
|
9
|
Gayther SA, Batley SJ, Linger L, Bannister
A, Thorpe K, Chin SF, Daigo Y, Russell P, Wilson A, Sowter HM, et
al: Mutations truncating the EP300 acetylase in human cancers. Nat
Genet. 24:300–303. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Phillips AC and Vousden KH:
Acetyltransferases and tumour suppression. Breast Cancer Res.
2:244–246. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiao XS, Cai MY, Chen JW, Guan XY, Kung
HF, Zeng YX and Xie D: High expression of p300 in human breast
cancer correlates with tumor recurrence and predicts adverse
prognosis. Chin J Cancer Res. 23:201–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He
JH, Wu QL and Cai MY: High expression of transcriptional
coactivator p300 correlates with aggressive features and poor
prognosis of hepatocellular carcinoma. J Transl Med. 9:52011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao ZW, Zhou TC, Tan XJ, Song XL, Liu Y,
Shi XY, Huang WJ, Du LL, Tu BJ and Lin XD: High expression of p300
is linked to aggressive features and poor prognosis of
nasopharyngeal carcinoma. J Transl Med. 10:1102012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao Y, Geng J, Hong X, Qi J, Teng Y, Yang
Y, Qu D and Chen G: Expression of p300 and CBP is associated with
poor prognosis in small cell lung cancer. Int J Clin Exp Pathol.
7:760–767. 2014.PubMed/NCBI
|
|
15
|
Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang
LJ and Yang HX: High expression of the transcriptional co-activator
p300 predicts poor survival in resectable non-small cell lung
cancers. Eur J Surg Oncol. 38:523–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huh JW, Kim HC, Kim SH, Park YA, Cho YB,
Yun SH, Lee WY and Chun HK: Prognostic impact of p300 expression in
patients with colorectal cancer. J Surg Oncol. 108:374–377. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishihama K, Yamakawa M, Semba S, Takeda H,
Kawata S, Kimura S and Kimura W: Expression of HDAC1 and CBP/p300
in human colorectal carcinomas. J Clin Pathol. 60:1205–1210. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grossman SR: p300/CBP/p53 interaction and
regulation of the p53 response. Eur J Biochem. 268:2773–2778. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grossman SR, Deato ME, Brignone C, Chan
HM, Kung AL, Tagami H, Nakatani Y and Livingston DM:
Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
Science. 300:342–344. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vleugel MM, Shvarts D, van der Wall E and
van Diest PJ: p300 and p53 levels determine activation of HIF-1
downstream targets in invasive breast cancer. Hum Pathol.
37:1085–1092. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barlev NA, Liu L, Chehab NH, Mansfield K,
Harris KG, Halazonetis TD and Berger SL: Acetylation of p53
activates transcription through recruitment of coactivators/histone
acetyltransferases. Mol Cell. 8:1243–1254. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyashita T and Reed JC: Tumor suppressor
p53 is a direct transcriptional activator of the human bax gene.
Cell. 80:293–299. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan ZM, Huang Y, Ishiko T, Nakada S,
Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R,
Shi Y, et al: Role for p300 in stabilization of p53 in the response
to DNA damage. J Biol Chem. 274:1883–1886. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Poller DN, Baxter KJ and Shepherd NA: p53
and Rb1 protein expression: Are they prognostically useful in
colorectal cancer? Br J Cancer. 75:87–93. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adrover E, Maestro ML, Sanz-Casla MT, del
Barco V, Cerdán J, Fernández C and Balibrea JL: Expression of high
p53 levels in colorectal cancer: A favourable prognostic factor. Br
J Cancer. 81:122–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Allegra CJ, Paik S, Colangelo LH, Parr AL,
Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N and Wieand HS:
Prognostic value of thymidylate synthase, Ki-67, and p53 in
patients with Dukes' B and C colon cancer: A National Cancer
Institute-National Surgical Adjuvant Breast and Bowel Project
collaborative study. J Clin Oncol. 21:241–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Giatromanolaki A, Sivridis E, Stathopoulos
GP, Fountzilas G, Kalofonos HP, Tsamandas A, Vrettou E, Scopa C,
Polychronidis A, Simopoulos K, et al: Bax protein expression in
colorectal cancer: Association with p53, bcl-2 and patterns of
relapse. Anticancer Res. 2:253–259. 2001.
|
|
28
|
Katkoori VR, Suarez-Cuervo C, Shanmugam C,
Jhala NC, Callens T, Messiaen L, Posey J III, Bumpers HL, Meleth S,
Grizzle WE, et al: Bax expression is a candidate prognostic and
predictive marker of colorectal cancer. J Gastrointest Oncol.
1:76–89. 2010.PubMed/NCBI
|
|
29
|
Schelwies K, Sturm I, Grabowski P,
Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO,
Zeitz M, et al: Analysis of p53/BAX in primary colorectal
carcinoma: Low BAX protein expression is a negative prognostic
factor in UICC stageIII tumors. Int J Cancer. 99:589–596. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kowalczyk AE, Krazinski BE, Godlewski J,
Kiewisz J, Kwiatkowski P, Sliwinska-Jewsiewicka A, Kiezun J,
Wierzbicki PM, Bodek G, Sulik M, et al: Altered expression of the
PLAGL1ZAC1/LOT1) gene in colorectal cancer: Correlations to the
clinicopathological parameters. Int J Oncol. 47:951–962.
2015.PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bundy JG, Iyer NG, Gentile MS, Hu DE,
Kettunen M, Maia AT, Thorne NP, Brenton JD, Caldas C and Brindle
KM: Metabolic consequences of p300 gene deletion in human colon
cancer cells. Cancer Res. 66:7606–7614. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bhandaru M, Ardekani GS, Zhang G, Martinka
M, McElwee KJ, Li G and Rotte A: A combination of p300 and Braf
expression in the diagnosis and prognosis of melanoma. BMC Cancer.
14:3982014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ionov Y, Matsui S and Cowell JK: A role
for p300/CREB binding protein genes in promoting cancer progression
in colon cancer cell lines with microsatellite instability. Proc
Natl Acad Sci USA101. 1273–1278. 2004. View Article : Google Scholar
|
|
35
|
Krubasik D, Iyer NG, English WR, Ahmed AA,
Vias M, Roskelley C, Brenton JD, Caldas C and Murphy G: Absence of
p300 induces cellular phenotypic changes characteristic of
epithelial to mesenchyme transition. Br J Cancer. 94:1326–1332.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peña C, García JM, García V, Silva J,
Domínguez G, Rodríguez R, Maximiano C, García de Herreros A, Muñoz
A and Bonilla F: The expression levels of the transcriptional
regulators p300 and CtBP modulate the correlations between SNAIL
ZEB1, E-cadherin and vitamin D receptor in human colon carcinomas.
Int J Cancer. 119:2098–2104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Goodman RH and Smolik S: CBP/p300 in cell
growth, transformation, and development. Genes Dev. 14:1553–1577.
2000.PubMed/NCBI
|
|
38
|
Zhou J, Zhan S, Tan W, Cheng R, Gong H and
Zhu Q: P300 binds to and acetylates MTA2 to promote colorectal
cancer cells growth. Biochem Biophys Res Commun. 444:387–390. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Debes JD, Sebo TJ, Lohse CM, Murphy LM,
Haugen DA and Tindall DJ: p300 in prostate cancer proliferation and
progression. Cancer Res. 63:7638–7640. 2003.PubMed/NCBI
|
|
40
|
Gry M, Rimini R, Strömberg S, Asplund A,
Pontén F, Uhlén M and Nilsson P: Correlations between RNA and
protein expression profiles in 23 human cell lines. BMC Genomics.
10:3652009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen G, Gharib TG, Huang CC, Taylor JM,
Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB,
Hanash SM, et al: Discordant protein and mRNA expression in lung
adenocarcinomas. Mol Cell Proteomics. 1:304–313. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lichtinghagen R, Musholt PB, Lein M, Römer
A, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA and
Jung K: Different mRNA and protein expression of matrix
metalloproteinases 2 and 9 and tissue inhibitor of
metalloproteinases 1 in benign and malignant prostate tissue. Eur
Uro. l42:398–406. 2002. View Article : Google Scholar
|
|
43
|
Iyer NG, Chin SF, Ozdag H, Daigo Y, Hu DE,
Cariati M, Brindle K, Aparicio S and Caldas C: p300 regulates
p53-dependent apoptosis after DNA damage in colorectal cancer cells
by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA101.
7386–7391. 2004. View Article : Google Scholar
|
|
44
|
Shi D, Pop MS, Kulikov R, Love IM, Kung AL
and Grossman SR: CBP and p300 are cytoplasmic E4 polyubiquitin
ligases for p53. Proc Natl Acad Sci USA. 106:16275–16280. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ito A, Lai CH, Zhao X, Saito S, Hamilton
MH, Appella E and Yao TP: p300/CBP-mediated p53 acetylation is
commonly induced by p53-activating agents and inhibited by MDM2.
EMBO J. 20:1331–1340. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Theodoropoulos GE, Karafoka E, Papailiou
JG, Stamopoulos P, Zambirinis CP, Bramis K, Panoussopoulos SG,
Leandros E and Bramis J: P53 and EGFR expression in colorectal
cancer: A reappraisal of ‘old’ tissue markers in patients with long
follow-up. Anticancer Res. 29:785–791. 2009.PubMed/NCBI
|
|
47
|
Iacopetta B: TP53 mutation in colorectal
cancer. Hum Mutat. 21:271–276. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tomoda H and Kakeji Y: Immunohistochemical
analysis of p53 in colorectal cancer regarding clinicopathological
correlation and prognostic significance. J Surg Oncol. 58:125–128.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Morikawa T, Kuchiba A, Liao X, Imamura Y,
Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS,
et al: Tumor TP53 expression status, body mass index and prognosis
in colorectal cancer. Int J Cancer. 131:1169–1178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS,
Charytonowicz E, Guillem JG, Cordon-Cardo C and Cohen AM: p53
nuclear overexpression: An independent predictor of survival in
lymph nodepositive colorectal cancer patients. J Clin Oncol12.
2043–2050. 1994. View Article : Google Scholar
|
|
51
|
Ahnen DJ, Feigl P, Quan G,
Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD,
Macdonald JS and Meyskens FL Jr: Ki-ras mutation and p53
overexpression predict the clinical behavior of colorectal cancer:
A Southwest Oncology Group study. Cancer Res. 58:1149–1158.
1998.PubMed/NCBI
|
|
52
|
Thomas A and White E: Suppression of the
p300-dependent mdm2 negative-feedback loop induces the p53
apoptotic function. Genes Dev. 12:1975–1985. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
De Angelis PM, Stokke T, Thorstensen L,
Lothe RA and Clausen OP: Apoptosis and expression of Bax, Bcl-x,
and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas,
and association with p53 genotype/phenotype. Mol Pathol51. 254–261.
1998. View Article : Google Scholar
|
|
54
|
Sturm I, Papadopoulos S, Hillebrand T,
Benter T, Lück HJ, Wolff G, Dörken B and Daniel PT: Impaired BAX
protein expression in breast cancer: Mutational analysis of the BAX
and the p53 gene. Int J Cancer. 87:517–521. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wincewicz A, Sulkowska M, Koda M and
Sulkowski S: Cumulative expression of HIF-1-alpha, Bax, Bcl-xL and
P53 in human colorectal cancer. Pathology. 39:334–338. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jansson A and Sun XF: Bax expression
decreases significantly from primary tumor to metastasis in
colorectal cancer. J Clin Oncol20. 811–816. 2002. View Article : Google Scholar
|
|
57
|
Cobanoglu B, Ceyran AB, Simsek M and Şenol
S: Immunohistochemical analysis of Bax and AIF in colorectal
tumors. Int J Clin Exp Med. 8:16071–16076. 2015.PubMed/NCBI
|
|
58
|
Krajewska M, Moss SF, Krajewski S, Song K,
Holt PR and Reed JC: Elevated expression of Bcl-X and reduced Bak
in primary colorectal adenocarcinomas. Cancer Res. 56:2422–2427.
1996.PubMed/NCBI
|
|
59
|
Bargou RC, Daniel PT, Mapara MY, Bommert
K, Wagener C, Kallinich B, Royer HD and Dörken B: Expression of the
bcl-2 gene family in normal and malignant breast tissue: Low
bax-alpha expression in tumor cells correlates with resistance
towards apoptosis. Int J Cancer. 60:854–859. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Paul-Samojedny M, Kokocińska D, Samojedny
A, Mazurek U, Partyka R, Lorenz Z and Wilczok T: Expression of cell
survival/death genes: Bcl-2 and Bax at the rate of colon cancer
prognosis. Biochim Biophys Acta. 1741:25–29. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ogura E, Senzaki H, Yamamoto D, Yoshida R,
Takada H, Hioki K and Tsubura A: Prognostic significance of Bcl-2,
Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol
Rep6. 365–369. 1999.
|
|
62
|
Koda M, Reszec J, Sulkowska M,
Kanczuga-Koda L and Sulkowski S: Expression of the insulin-like
growth factor-I receptor and proapoptotic Bax and Bak proteins in
human colorectal cancer. Ann NY Acad Sci. 1030:377–383. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Nehls O, Hass HG, Okech T, Zenner S, Hsieh
CJ, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Porschen R, et al:
Prognostic implications of BAX protein expression and
microsatellite instability in all non-metastatic stages of primary
colon cancer treated by surgery alone. Int J Colorectal Dis.
24:655–663. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bukholm IK and Nesland JM: Protein
expression of p53, p21WAF1/CIP1, bcl-2, Bax, cyclin D1 and pRb in
human colon carcinomas. Virchows Arch. 436:224–228. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Binder C, Marx D, Binder L, Schauer A and
Hiddemann W: Expression of Bax in relation to Bcl-2 and other
predictive parameters in breast cancer. Ann Oncol. 7:129–133. 1996.
View Article : Google Scholar : PubMed/NCBI
|
